Compare Stocks: TCRT, ATYR, RADX, and NEUP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.19 +0.7%	$0.41	$0.17 ▼ $1.11	$17.95M	0.91	2.49 million shs	894,720 shs
NEUP Neuphoria Therapeutics	$3.31 -0.2%	$3.69	$3.19 ▼ $17.19	$17.88M	0.75	90,028 shs	37,770 shs
RADX Radiopharm Theranostics	$1.04 -3.9%	$1.94	$0.90 ▼ $16.25	$16.30M	1.78	93,156 shs	87,453 shs
TCRT Alaunos Therapeutics	$2.69 +23.2%	$1.51	$0.72 ▼ $4.50	$6.77M	-0.87	2.13 million shs	26.39 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+0.27%	-28.01%	-52.77%	-63.96%	-81.98%
NEUP Neuphoria Therapeutics	+2.16%	-1.19%	-12.43%	-2.93%	-80.80%
RADX Radiopharm Theranostics	-3.57%	-2.70%	-28.95%	-75.62%	-84.81%
TCRT Alaunos Therapeutics	+5.31%	+179.13%	+54.61%	+6.34%	-31.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.19 +0.7%	$0.41	$0.17 ▼ $1.11	$17.95M	0.91	2.49 million shs	894,720 shs
NEUP Neuphoria Therapeutics	$3.31 -0.2%	$3.69	$3.19 ▼ $17.19	$17.88M	0.75	90,028 shs	37,770 shs
RADX Radiopharm Theranostics	$1.04 -3.9%	$1.94	$0.90 ▼ $16.25	$16.30M	1.78	93,156 shs	87,453 shs
TCRT Alaunos Therapeutics	$2.69 +23.2%	$1.51	$0.72 ▼ $4.50	$6.77M	-0.87	2.13 million shs	26.39 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+0.27%	-28.01%	-52.77%	-63.96%	-81.98%
NEUP Neuphoria Therapeutics	+2.16%	-1.19%	-12.43%	-2.93%	-80.80%
RADX Radiopharm Theranostics	-3.57%	-2.70%	-28.95%	-75.62%	-84.81%
TCRT Alaunos Therapeutics	+5.31%	+179.13%	+54.61%	+6.34%	-31.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
NEUP Neuphoria Therapeutics	1.67	Reduce	$7.00	111.80% Upside
RADX Radiopharm Theranostics	2.33	Hold	$11.00	959.73% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, ATYR, RADX, and NEUP Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	RADX Radiopharm Theranostics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/16/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	RADX Radiopharm Theranostics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	95.51	N/A	N/A	$0.69 per share	0.27
NEUP Neuphoria Therapeutics	$1.17M	15.23	N/A	N/A	$4.55 per share	0.73
RADX Radiopharm Theranostics	$1.88M	8.67	N/A	N/A	$1.28 per share	0.81
TCRT Alaunos Therapeutics	$3K	2,273.30	N/A	N/A	$0.93 per share	2.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$13.45M	-$6.22	N/A	N/A	N/A	N/A	-38.31%	-28.92%	N/A
RADX Radiopharm Theranostics	-$38.65M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-232.60%	-158.99%	11/17/2026 (Estimated)

Latest TCRT, ATYR, RADX, and NEUP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ATYR aTyr Pharma	-$0.11	N/A	N/A	N/A	$2.50 million	N/A
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	N/A
7/31/2026	Q4 2026	RADX Radiopharm Theranostics	N/A	-$0.81	N/A	-$0.8050	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
NEUP Neuphoria Therapeutics	N/A	27.83	27.83
RADX Radiopharm Theranostics	N/A	1.16	1.16
TCRT Alaunos Therapeutics	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
NEUP Neuphoria Therapeutics	15.90%
RADX Radiopharm Theranostics	N/A
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.03%
NEUP Neuphoria Therapeutics	1.55%
RADX Radiopharm Theranostics	N/A
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	58	98.09 million	93.15 million	Optionable
NEUP Neuphoria Therapeutics	8	5.41 million	5.33 million	N/A
RADX Radiopharm Theranostics	14	15.70 million	N/A	N/A
TCRT Alaunos Therapeutics	1	2.54 million	2.13 million	No Data

TCRT, ATYR, RADX, and NEUP Headlines

Recent News About These Companies

Bio Pre-Market Movers: TCRT, ICCC, MNDR Chart The Course

October 13 at 3:03 PM | rttnews.com

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

October 13 at 3:03 PM | finance.yahoo.com

Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge

October 13 at 3:03 PM | finance.yahoo.com

Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and Funding

October 13 at 3:03 PM | investorideas.comI

Alaunos Therapeutics Acquires Velaris Therapeutics, Secures $350 Million Private Placement to Advance Pulmonary Hypertension Pipeline

October 13 at 10:51 AM | quiverquant.comQ

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

October 13 at 7:00 AM | prnewswire.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Falls 3% - What's Next?

October 6, 2026 | americanbankingnews.com

Alaunos Therapeutics Announces New Registered Direct Offering

September 22, 2026 | tipranks.com

Alaunos Prices $1.12M Registered Direct Offering

September 19, 2026 | rttnews.com

Alaunos Therapeutics Stock Falls 17% After Public Offering Announcement

September 19, 2026 | rttnews.com

Alaunos Therapeutics prices direct offering at $1.46 per share

September 19, 2026 | streetinsider.com

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

September 18, 2026 | globenewswire.com

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

September 18, 2026 | benzinga.com

Alaunos Therapeutics Updates Bylaws to Ease Shareholder Quorum

September 17, 2026 | tipranks.com

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, ATYR, RADX, and NEUP Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.18 +0.00 (+0.65%)

As of 01:24 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Neuphoria Therapeutics NASDAQ:NEUP

$3.30 -0.01 (-0.15%)

As of 01:17 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Radiopharm Theranostics NASDAQ:RADX

$1.04 -0.04 (-3.89%)

As of 01:23 PM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Alaunos Therapeutics NASDAQ:TCRT

$2.68 +0.51 (+23.17%)

As of 01:25 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, ATYR, RADX, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, ATYR, RADX, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, ATYR, RADX, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, ATYR, RADX, and NEUP Company Descriptions

aTyr Pharma NASDAQ:ATYR

Neuphoria Therapeutics NASDAQ:NEUP

Radiopharm Theranostics NASDAQ:RADX

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, ATYR, RADX, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, ATYR, RADX, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, ATYR, RADX, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, ATYR, RADX, and NEUP Company Descriptions

aTyr Pharma NASDAQ:ATYR

Neuphoria Therapeutics NASDAQ:NEUP

Radiopharm Theranostics NASDAQ:RADX

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools